<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Ariana Pharma]]></title><description><![CDATA[Turning Data into Clinical Breakthroughs]]></description><link>https://www.arianapharma.com/blog</link><generator>RSS for Node</generator><lastBuildDate>Wed, 21 Oct 2026 14:00:34 GMT</lastBuildDate><atom:link href="https://www.arianapharma.com/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Ariana Pharma and USIL Therapeutics Announce AI-Powered Collaboration to Advance Development of UT-241 in Acute Radiation Syndrome]]></title><description><![CDATA[Ariana's explainable AI applied to mechanistic modelling of radiation-induced oxidative stress, bridging pre-clinical evidence to clinical outcomes. Ariana Pharma® and USIL Therapeutics, a Luxembourg-based biopharmaceutical company developing innovative cytoprotective therapies, today announced a collaboration to develop a mechanistic AI model supporting the clinical evaluation of UT-241 in acute radiation syndrome (ARS). The collaboration addresses a critical unmet medical need. Acute...]]></description><link>https://www.arianapharma.com/post/ariana-pharma-and-usil-therapeutics-announce-ai-powered-collaboration-to-advance-development-of-ut-2</link><guid isPermaLink="false">6a9eb15b99445722049f01c1</guid><pubDate>Tue, 01 Sep 2026 12:29:52 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/f9d17b_b4296ff2bd4f47d387036c91cd6167af~mv2.jpg/v1/fit/w_1000,h_352,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>arianapharma</dc:creator></item><item><title><![CDATA[A New Chapter: Ariana Pharma Appoints Thomas Turcat as Chief Executive Officer]]></title><description><![CDATA[Ariana Pharma announces the appointment of Thomas Turcat as Chief Executive Officer. The transition marks a new chapter for Ariana Pharma as it expands the reach of its explainable AI technology with in-house drug development expertise - transforming small, heterogeneous clinical cohorts into regulatory-ready results that are logical and rule-association-based, while leveraging Thomas's broad commercial expertise. The output is transparent and explainable, giving research teams evidence they...]]></description><link>https://www.arianapharma.com/post/a-new-chapter-ariana-pharma-appoints-thomas-turcat-as-chief-executive-officer</link><guid isPermaLink="false">6a9eb15b99445722049f01c4</guid><pubDate>Tue, 07 Jul 2026 22:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/f9d17b_c7d12fb4727643d0a34ac2c340cf92ad~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>arianapharma</dc:creator></item><item><title><![CDATA[eXp AI-Driven Discovery of Genomic Biomarkers for Liver Toxicity Risk — A UK Biobank Case Study]]></title><description><![CDATA[Shteto, A., Boulahfa, J., Etcheto, A. et al. Genomic biomarkers of liver toxicity risk from UK Biobank data. Pharmacogenomics J 25, 30 (2025). Toxic liver disease represents one of the most serious safety challenges in drug development and clinical practice. In this study, Ariana Pharmaceuticals harnessed the power of explainable AI (eXp AI) through its proprietary KEM® (Knowledge Extraction &#38; Management) platform to uncover genomic biomarkers associated with increased mortality risk in liver...]]></description><link>https://www.arianapharma.com/post/exp-ai-driven-discovery-of-genomic-biomarkers-for-liver-toxicity-risk-a-uk-biobank-case-study</link><guid isPermaLink="false">6a9eb15b99445722049f01c5</guid><pubDate>Wed, 17 Dec 2025 23:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_5cc454c238df46aeaf3f6d2d492bc9db~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>arianapharma</dc:creator></item><item><title><![CDATA[Ariana Pharmaceuticals Publishes New Study on AI-Driven Discovery of Genomic Biomarkers for Liver Toxicity Risk]]></title><description><![CDATA[New Real-World Evidence study, "eXp AI-Driven Discovery of Genomic Biomarkers for Liver Toxicity Risk - A UK Biobank Case Study," published in The Pharmacogenomics Journal Ariana Pharmaceuticals is proud to announce the publication of a new Real-World Evidence study in The Pharmacogenomics Journal. This research showcases how Ariana's explainable AI (eXp AI) and proprietary KEM® platform can identify genomic biomarkers associated with mortality risk in toxic liver disease, using data from the...]]></description><link>https://www.arianapharma.com/post/ariana-pharmaceuticals-publishes-new-study-on-ai-driven-discovery-of-genomic-biomarkers-for-liver-to</link><guid isPermaLink="false">6a9eb15b99445722049f01c3</guid><pubDate>Thu, 11 Dec 2025 13:37:19 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/11062b_5647e37eb5cf4f5480d52b1430337fca~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>arianapharma</dc:creator></item><item><title><![CDATA[KEM®-Based Genomic Signature Predicts NADT Response in High-Risk Prostate Cancer]]></title><description><![CDATA[Identification of a Predictive Genomic Signature for NADT Response in High-Risk Prostate Cancer Using Real-World Clinical Trial Data Analyzed by the KEM® Explainable AI Platform. Presented as a scientific poster at ESMO-AI 2025, Berlin. Prostate cancer is one of the most common malignancies worldwide, and treatment decisions for localized high-risk disease increasingly rely on molecular predictors to guide therapy selection. Neoadjuvant androgen deprivation therapy (NADT) can improve outcomes...]]></description><link>https://www.arianapharma.com/post/kem-based-genomic-signature-predicts-nadt-response-in-high-risk-prostate-cancer</link><guid isPermaLink="false">6a9eb15b99445722049f01bf</guid><pubDate>Mon, 24 Nov 2025 23:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_4c6e764345585177432d6f~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>arianapharma</dc:creator></item><item><title><![CDATA[Optimal First- and Last-Line Treatment Strategies in IBD Using Real-World Data - The IBD-Drive Project]]></title><description><![CDATA[Identification of Optimal First- and Last-Line Advanced Treatment Strategies in IBD Using Real-World Data Analyzed by the KEM® Explainable AI Platform: Proof of Concept from the IBD-Drive Project. Presented at Journées Francophones d'Hépato-gastroentérologie et d'Oncologie Digestive 2025 (JFHOD). Chronic Inflammatory Bowel Diseases (IBD) - including Crohn's disease and ulcerative colitis - are characterized by chronic inflammation of the digestive tract that can damage the intestine and...]]></description><link>https://www.arianapharma.com/post/optimal-first-and-last-line-treatment-strategies-in-ibd-using-real-world-data-the-ibd-drive-proje</link><guid isPermaLink="false">6a9eb15b99445722049f01c0</guid><pubDate>Wed, 11 Jun 2025 22:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/f9d17b_d2dd0f893620414a9586c3bb59d50b3b~mv2.jpg/v1/fit/w_1000,h_628,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>arianapharma</dc:creator></item><item><title><![CDATA[Best Therapeutic Sequence of Second-Line Biologics After Anti-TNF or Vedolizumab in IBD]]></title><description><![CDATA[Routine care data analyzed using explainable AI identify the best therapeutic sequence of 2nd-line biologic treatments after a 1st line with Anti-TNF or Vedolizumab in inflammatory bowel disease. Presented at United European Gastroenterology 2024 (UEG). Inflammatory bowel disease (IBD) - including Crohn's disease and ulcerative colitis - is characterized by chronic inflammation of the gastrointestinal tract, which can damage the bowel and cause serious disabilities. Treatments only have a...]]></description><link>https://www.arianapharma.com/post/best-therapeutic-sequence-of-second-line-biologics-after-anti-tnf-or-vedolizumab-in-ibd</link><guid isPermaLink="false">6a9eb15b99445722049f01c2</guid><pubDate>Wed, 12 Jun 2024 22:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/f9d17b_96dff400ab494bb7ac6ac9ad09e9dc17~mv2.jpg/v1/fit/w_480,h_270,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>arianapharma</dc:creator></item></channel></rss>